Checkpoint Therapeutics
CKPT
CKPT was delisted on the 29th of May, 2025.
3 hedge funds and large institutions have $699K invested in Checkpoint Therapeutics in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
36% more capital invested
Capital invested by funds: $514K → $699K (+$185K)
0.04% more ownership
Funds ownership: 0.06% → 0.1% (+0.04%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$349K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$157 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OPPM
1
Opus Point Partners Management
New York
| $438K | – | – | – |
|
|
2
Royal Bank of Canada
Toronto,
Ontario, Canada
| $258K | +$349K | +6,659 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $3K | +$157 | +3 | +4% |
|
CKPT Hedge Fund Activity: Q4 2017 in Review
3 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q4 2017, worth a combined $699K — up 36% from $514K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new CKPT positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Royal Bank of Canada, opening a new position worth an estimated $349K.
- 3 institutional investors held Checkpoint Therapeutics (CKPT) as of Q4 2017, up from 2 in Q3 2017.
- Funds reported $699K of Checkpoint Therapeutics stock for Q4 2017, up 36% quarter-over-quarter.
- 1 fund opened new Checkpoint Therapeutics positions in Q4 2017 and 0 closed out, a net change of +1 holder.
- The largest Checkpoint Therapeutics buyer in Q4 2017 was Royal Bank of Canada, an estimated $349K added.
Based on aggregated 13F filings for Q4 2017.